Therapeutic effect of umbilical cord mesenchymal stem cells on renal ischemia-reperfusion injury

  • Acta Pharm. 2025 Apr 10;75(1):103-118. doi: 10.2478/acph-2025-0006.
Liang Xiao  1 ,  Chengyu Huang  2 ,  Shanghua Xiao  2 ,  Lingfeng Xie  2 ,  Xueyan Zhang  2 ,  Fucheng Xiao  3 ,  Huajia Cai  4 ,  Shuibo Yang  5 ,  Shengqing Wu  2 ,  Shoukang Qu  2 ,  Jia Liu  2  5
Affiliations
  • 1. 1Department of Surgery and Oncology, Shenzhen Second People's Hospital/the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, 518035, China.
  • 2. 2Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen, Guangdong 518107, China.
  • 3. 3The Center of Campus, Shenzhen Senior High School Group, Shenzhen, Guangdong 518040, China.
  • 4. 4Psychiatric Medicine Sophomore, Southern Medical University, Guangzhou, Guangdong 510515, China.
  • 5. 5School of Agriculture and Biotechnology Shenzhen Campus of Sun Yat-sen University Shenzhen, Guangdong 518107, China.
PMID: 40208785 DOI: 10.2478/acph-2025-0006
Abstract

Acute kidney injury (AKI) is a growing global health issue with no effective treatments. This study evaluates the therapeutic effects of umbilical cord mesenchymal stem cells (UC-MSCs) on AKI caused by ischemia-reperfusion injury (IRI) in mice. Thirty mice were divided into a sham group, an IRI group, and an MSC-treated group. Renal function was assessed, and histological analysis, immunofluorescence, and Real-Time PCR were used to evaluate renal damage, inflammatory cell presence, and cytokine expression (TNF-α, IL-6, IL-10). Results showed that MSC treatment reduced renal damage, decreased pro-inflammatory cytokines (TNF-α, IL-6), increased anti-inflammatory IL-10, and promoted kidney repair by homing to injury sites. Thus, umbilical cord MSCs may mitigate AKI by reducing inflammation and enhancing renal repair.

Keywords
acute kidney injury; inflammation; renal ischemia-reperfusion; umbilical cord mesenchymal stem cells.
Products
Inhibitors & Agonists
Other Products